2-(PENTADECYL)-FURAN


Synonyms	2-(Pentadecyl)-Furan
Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	LSVQFJUSRLOULU-UHFFFAOYSA-N
Smiles	CCCCCCCCCCCCCCCc1occc1
InChI	InChI=1S/C19H34O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-16-19-17-15-18-20-19/h15,17-18H,2-14,16H2,1H3

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C19H34O
Molecular Weight	278.47
AlogP	7.68
Hydrogen Bond Acceptor	0.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	14.0
Polar Surface Area	13.14
Molecular species	None
Aromatic Rings	1.0
Heavy Atoms	20.0

Assay Description	Organism	Bioactivity
Insecticidal activity against Spodoptera exigua larvae assessed as inhibition of larval growth at 5 umol/g of diet administered through compound containing diet after 7 days	Spodoptera exigua	98.0 %
Insecticidal activity against Spodoptera exigua larvae assessed as induction of larval mortality at 5 umol/g of diet administered through compound containing diet after 7 days	Spodoptera exigua	None
Insecticidal activity against older Spodoptera exigua larvae assessed per ug of diet	Spodoptera exigua	3000.0 nM
Insecticidal activity against young Spodoptera exigua larvae assessed per ug of diet	Spodoptera exigua	2000.0 nM

Cross References

Resources	Reference
ChEMBL	CHEMBL508291
PubChem	181250
SureChEMBL	SCHEMBL775269

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).